Keynote presentation

Professor Christel Faes from Hasselt University (Belgium) will give the keynote presentation.

Back to top


Invited sessions

Statistical Methods for Platform Trials

Speakers Title
Marta Bofill (invited) Design and Analysis of Platform Trials Incorporating Non-concurrent Controls
Michael Krams Platform Trials: The Good, the Bad and the Ugly A Clinical Perspective
Peter Jacko Allocation Ratios Achieving Maximal Power in Controlled Experiments: Implications for Randomization in Two-Arm, Umbrella and Platform Trials
Thomas Jaki RECOVERY - an adaptive platform trial

organised by Franz König

Back to top


The Siren’s of Estimands: Temptations and Perils in ICH E9 (R1)

Speakers Title
Senn Stephen (invited) Good Things Come To Those Who Weight – Appropriately
Akacha Mouna Unlocking the Power of Estimands and Causal Thinking
Uschner Diane Using Randomization Tests to Address Disruptions in Clinical Trials: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions
Klinglmüller Florian Estimands in Regulatory Decision-Making: Opportunities, Challenges, and Evolving

organised by Franz König

Back to top


Contrasting Bayesian and frequentist model building for descriptive research questions - a paired-design experiment of STRATOS-TG2

Speakers Title
Mariana Nold (invited) Contrasting Bayesian And Frequentist Model Building For Descriptive Research Questions - A Paired-design Experiment
Michael Kammer Bayesian and Frequentist Workflows in Practice, Part 1: Prediction of Bacteremia, a School-belonging Re-analysis and how Multiple Imputation Bridges Two Worlds
Aliaksandr Hubin Bayesian and Frequentist Workflows in Practice, Part 2: Insights From the Kepler Task and Bacteremia Task Reanalysis with a Focus on Bayesian Model Averaging
Georg Heinze Bayesian and Frequentist Workflows in Practice, Part 3: Kepler’s Third Law, Bodyfat, and the Beauty of Descriptive Models

organised by Georg Heinze

Back to top


Topic-contributed sessions

News from INVENTS - a research consortium for drug development for rare diseases

Speakers Title
Tim Friede Methods for Clinical Research in Rare Diseases
Laurens Suijterman A Closer Look at Regulatory Evaluation Frameworks for Model-Informed Drug Development for Rare Diseases
Andy Hooker Model-Based Approaches in Rare-Disease Clinical Trials - Using Nonlinear Mixed-effects Models for Design and Analysis
Sarah Zohar Discussion of Contributors

organised by Marc Vandemeulebroecke

Back to top


Assessing treatment effect heterogeneity in clinical trials

Speakers Title
Tobias Freidling Selective Randomization Inference For Adaptive Experiments
Susanne Dandl Heterogeneous Treatment Effect Estimation for Observational Data Using Model-based Forests
Sebastian Weber A Critical Benchmark Of Bayesian Shrinkage Estimation For Subgroup Analysis
Florian Klinglmueller Discussion of Contributors

organised by Kostas Sechidis, Bjoern Bornkamp and Frank Bretz

Back to top


Methods for meta-analysis with very few studies

Speakers Title
Ralf Bender Challenges of Meta-Analyses with Very Few Studies
Stefan Embacher The Beta-Binomial Model
Sibylle Sturtz Bayesian Random-Effects Meta-Analysis With Informative Priors For The Heterogeneity Parameter
Leo Held A New Method For Meta-analysis With Very Few Studies

organised by Ralf Bender

Back to top


Towards best practices in medical statistics: The need to implement innovative scientific solutions

Speakers Title
Mouna Akacha From Eureka to Patients: Unraveling the Path from Invention to Adoption
Franz Koenig From Concept to Practice: Implementing New Concepts for Platform Trials in Depression – Insights from the EU-PEARL Project and its offsprings
Theresa Ullmann Neutral Comparisons Of Statistical Methods: Opportunities, Challenges, And Common Issues
Andy Grieve Discussion of Contributors

organised by Frank Bretz

Back to top


Exploring the dosing regimen in phase I Oncology dose escalation trials

Speakers Title
Lukas Widmer Guiding Oncology Phase I Dose Escalation for Modern Therapies with Short to Long-term Safety Monitoring, Incorporating Actual Dosing History and Variable Dosing Regimens
Moreno Ursino Bayesian Dose Regimen Assessment in Early Phase Oncology Incorporating
Christina Habermehl Dose Optimization in Early Oncology Studies: a Practical Example of a Cross-functional Approach in the PROCEADE-CRC-01 Phase 1 Study of the Antibody-drug-conjugate M9140
Thomas Jaki Discussion of Contributors

organised by Sebastian Weber

Back to top


Sample Size Calculation in Clinical Trials

Speakers Title
Robin Ristl Sample Size Calculation To The People
Gernot Wassmer Rpact: An R Package For Adaptive Clinical Trials
Elias Laurin Why And How Should We Simulate Clinical Trials?
Lukas Baumann A Simulation Based Approach to Estimating Sample Sizes for Clinical Trials

organised by Robin Ristl

Back to top


Young statisticians

Speakers Title
Luca Althaus Modeling And Comparisons Of Adverse Event Burden Score, A Versatile Summary Measure Integrating Event Frequency, Duration And Severity
Hana Šinkovec Cross-Sectoral Comparisons of Process Quality Indicators of Health Care Across Residential Regions Using Restricted Mean Survival Time
Manuel M. Müller Isotonic subgroup selection
Cinzia Anna Maria Papappicco Potential Of Random Survival Forest In Providing Reliable Predictors In A Very Small Dataset
Han Chang Chiam Selection Bias in Hybrid Randomized Controlled Trials Using External Controls

organised by Andrea Berghold

Back to top